Publications by authors named "Alessandra Lugaresi"

100Publications

Determinants of therapeutic lag in multiple sclerosis.

Mult Scler 2021 Jan 11:1352458520981300. Epub 2021 Jan 11.

CORe, Department of Medicine, University of Melbourne, Melbourne, VIC, Australia/Melbourne MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia.

View Article and Find Full Text PDF
January 2021

Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.

Neurology 2020 Dec 28. Epub 2020 Dec 28.

From the Tomas Kalincik, Sifat Sharmin, Charles Malpas, Ibrahima Diouf; CORe, Department of Medicine, University of Melbourne, Melbourne, Australia; Melbourne MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, AustraliaTim Spelman; Karolinska Institute, Stockholm, Sweden; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia; Burnet Institute, Melbourne, AustraliaDana Horakova, Eva Kubala Havrdova; Department of Neurology and Center of Clinical Neuroscience, General University Hospital and Charles University in Prague, Prague, Czech RepublicMaria Trojano; Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, ItalyGuillermo Izquierdo; Hospital Universitario Virgen Macarena, Sevilla, SpainAlessandra Lugaresi; Department of Neuroscience, Imaging and Clinical Sciences, University"G. d'Annunzio", Chieti, Italy; Department of Biomedical and Neuromotor Sciences, University of Bologna; IRCCS Istituto delle Scienze Neurologiche di BolognaAlexandre Prat, Marc Girard, Pierre Duquette; Hopital Notre Dame, Montreal, Canada; CHUM and Universite de Montreal, Montreal, CanadaPierre Grammond; CISSS Chaudière-Appalache, Levis, CanadaVilija Jokubaitis, Anneke van der Walt, Olga Skibina; Department of Neurology, Alfred Hospital, Melbourne, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, AustraliaFrancois Grand'Maison; Neuro Rive-Sud, Quebec, CanadaPatrizia Sola, Diana Ferraro; Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, ItalyVahid Shaygannejad; Isfahan University of Medical Sciences, Isfahan, IranRaed Alroughani; Amiri Hospital, Kuwait City, KuwaitRaymond Hupperts; Zuyderland Ziekenhuis, Sittard, NetherlandsMurat Terzi; Medical Faculty, 19 Mayis University, Samsun, TurkeyCavit Boz; KTU Medical Faculty Farabi Hospital, Karadeniz Technical University, Trabzon, TurkeyJeannette Lechner-Scott; School of Medicine and Public Health, University Newcastle, Newcastle, Australia; Department of Neurology, John Hunter Hospital, Newcastle, AustraliaEugenio Pucci; UOC Neurologia, Azienda Sanitaria Unica Regionale Marche - AV3, Macerata, ItalyVincent Van Pesch; Cliniques Universitaires Saint-Luc, Brussels, BelgiumFranco Granella; University of Parma, Parma, ItalyRoberto Bergamaschi; C. Mondino National Neurological Institute, Pavia, ItalyDaniele Spitaleri; Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, ItalyMark Slee; Flinders University, Adelaide, AustraliaSteve Vucic; Westmead Hospital, Sydney, AustraliaRadek Ampapa; Nemocnice Jihlava, Jihlava, Czech RepublicPamela McCombe; University of Queensland, Brisbane, Australia; Royal Brisbane and Women's Hospital, Brisbane, AustraliaCristina Ramo-Tello; Hospital Germans Trias i Pujol, Badalona, SpainJulie Prevost; CSSS Saint-Jérôme, Saint-Jerome, CanadaJavier Olascoaga; Hospital Universitario Donostia, Paseo de Begiristain, San Sebastián, SpainEdgardo Cristiano; Hospital Italiano, Buenos Aires, ArgentinaMichael Barnett; Brain and Mind Centre, University of Sydney, Sydney, AustraliaMaria Laura Saladin; INEBA - Institute of Neuroscience Buenos Aires, Buenos Aires, ArgentinaJose Luis Sanchez-Menoyo; Hospital de Galdakao-Usansolo, Galdakao, SpainSuzanne Hodgkinson; Liverpool Hospital, Sydney, AustraliaCsilla Rozsa; Jahn Ferenc Teaching Hospital, Budapest, HungaryStella Hughes; Craigavon Area Hospital, Craigavon, United KingdomFraser Moore; Jewish General Hospital, Montreal, CanadaCameron Shaw; Deakin University, Geelong, AustraliaErnest Butler; Monash Medical Centre, Melbourne, AustraliaOrla Gray; South East Trust, Belfast, United KingdomAllan Kermode; Perron Institute, University of Western Australia, Nedlands, Australia; Institute of Immunology and Infectious Diseases, Murdoch University, Perth, Australia; Sir Charles Gairdner Hospital, Perth, AustraliaTunde Csepany; Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, HungaryBhim Singhal; Bombay Hospital Institute of Medical Sciences, Mumbai, IndiaNeil Shuey; St Vincents Hospital, Fitzroy, Melbourne, AustraliaImre Piroska; Veszprém Megyei Csolnoky Ferenc Kórház zrt., Veszprem, HungaryBruce Taylor, MD, PhD; Royal Hobart Hospital, Hobart, AustraliaMagdolna Simo, MD; Semmelweis University Budapest, Budapest, HungaryCarmen-Adella Sirbu; Central Military Emergency University Hospital, Bucharest, Romania; Titu Maiorescu University, Bucharest, RomaniaAttila Sas; BAZ County Hospital, Miskolc, HungaryHelmut Butzkueven; Department of Neurology, Alfred Hospital, Melbourne, Australia; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia; Box Hill Hospital, Melbourne, Australia.

View Article and Find Full Text PDF
December 2020

Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.

Neurology 2021 01 6;96(2):e214-e227. Epub 2020 Oct 6.

From the Department of Health Sciences (DISSAL) (F.B., M.P.S.), University of Genoa, Italy; CORe (T.K., C.M.), Department of Medicine, University of Melbourne, Australia; Department of Neurology (F.L.), Icahn School of Medicine at Mount Sinai, New York, NY; Department of Biostatistics (G.C.), University of Alabama at Birmingham; Department of Neurology and Center for Clinical Neuroscience (D.H., E.K.H.), First Medical Faculty, Charles University, Prague, Czech Republic; Department of Basic Medical Sciences, Neuroscience and Sense Organs (M. Trojano), University of Bari, Italy; Department of Neuroscience (A.P., M.G., P.D.), Faculty of Medicine, Université de Montréal, Quebec, Canada; Department of Neuroscience, Imaging, and Clinical Sciences (M.O.), University G. d'Annunzio, Chieti; IRCCS Istituto delle Scienze Neurologiche di Bologna (A.L.); Dipartimento di Scienze Biomediche e Neuromotorie (A.L.), Università di Bologna, Italy; Hospital Universitario Virgen Macarena (G. Izquierdo. S.E.), Sevilla, Spain; Department of Medical, Surgical Science and Advanced Technology "GF Ingrassia" (F.P.), University of Catania, Italy; Ondokuz Mayis University (M. Terzi), Department of Neurology, Samsun, Turkey; CISSS Chaudi're-Appalache (P.G.), Centre-Hospitalier, Levis, Quebec, Canada; IRCCS Mondino Foundation (R.B.), Pavia; Department of Neuroscience (P.S., D.F.), Azienda Ospedaliera Universitaria, Modena, Italy; Department of Neurology (S.O.), Dokuz Eylul University, Izmir, Turkey; Ospedali Riuniti di Salerno (G. Iuliano), Salerno, Italy; Department of Neurology (C.B.), Karadeniz Technical University, Trabzon, Turkey; Department of Neurology (R.H.), Zuyderland Medical Center, Sittard, the Netherlands; Neuro Rive-Sud (F.G.), Hôpital Charles LeMoyne, Greenfield Park, Quebec, Canada; Clinico San Carlos (C.O.-G), Madrid, Spain; Cliniques Universitaires Saint-Luc (V.v.P.); Université Catholique de Louvain (V.v.P.), Brussels, Belgium; UOC Neurologia (E.C.), Azienda Sanitaria Unica Regionale Marche-AV3, Macerata, Italy; Kommunehospitalet (T.P.), Arhus C, Denmark; Koc University (A.A.), School of Medicine; Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases (A.S.), Istanbul, Turkey; Hospital Germans Trias i Pujol (C.R.-T.), Badalona, Spain; University of Queensland (P.M.), Brisbane, Australia; Haydarpasa Numune Training and Research Hospital (R.T.), Istanbul, Turkey; Central Clinical School (H.B.), Monash University, Melbourne, Australia; The University of Texas Health Science Center at Houston (J.S.W.); Rehabilitation Unit (C.S.), "Mons. L. Novarese" Hospital, Moncrivello; and IRCCS Ospedale Policlinico San Martino (M.P.S.), Genoa, Italy.

View Article and Find Full Text PDF
January 2021

Ponesimod for the treatment of relapsing multiple sclerosis.

Expert Opin Pharmacother 2020 Nov 18;21(16):1955-1964. Epub 2020 Aug 18.

Dipartimento di Scienze Biomediche e Neuromotorie, Università UOSI Riabilitazione Sclerosi Multipla, di Bologna , Bologna, Italy.

View Article and Find Full Text PDF
November 2020

Circadian Activity Rhythm in Early Relapsing-Remitting Multiple Sclerosis.

J Clin Med 2019 Dec 15;8(12). Epub 2019 Dec 15.

Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Via Altura 3A, 40139 Bologna, Italy.

View Article and Find Full Text PDF
December 2019

Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium?

Expert Opin Pharmacother 2019 Aug 25;20(11):1309-1320. Epub 2019 Jun 25.

a Dipartimento di Scienze Biomediche e Neuromotorie , Università di Bologna , Bologna , Italy.

View Article and Find Full Text PDF
August 2019

Teeth loss after teriflunomide treatment: Casual or causal? A short case series.

Mult Scler Relat Disord 2018 Aug 30;24:120-122. Epub 2018 Jun 30.

Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum, University of Bologna, Bologna, Italy; IRCCS Institute of the Neurological Sciences of Bologna (ISNB), Bologna, Italy. Electronic address:

View Article and Find Full Text PDF
August 2018

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

Mult Scler 2018 10 31;24(12):1617-1626. Epub 2017 Aug 31.

Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia/Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia/Department of Neurology, Box Hill Hospital, Monash University, Melbourne, VIC, Australia.

View Article and Find Full Text PDF
October 2018

Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.

Neurol Sci 2017 Jan 18;38(1):53-59. Epub 2016 Oct 18.

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Largo Daneo 3, 16132, Genoa, Italy.

View Article and Find Full Text PDF
January 2017

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.

J Neurol Neurosurg Psychiatry 2016 10 13;87(10):1133-7. Epub 2016 Jun 13.

Department of Neurology, Royal Melbourne Hospital, Parkville, Victoria, Australia Department of Medicine (RMH), The University of Melbourne, Parkville, Victoria, Australia.

View Article and Find Full Text PDF
October 2016

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Neurol Clin Pract 2016 Apr;6(2):102-115

Department of Medicine and Melbourne Brain Centre at the Royal Melbourne Hospital (TS, TK, VJ, HB), University of Melbourne, Australia; Biogen Idec Inc. (AZ, FP, SB, RH), Cambridge, MA; Department of Neurology (HW), University of Münster, Germany; Groene Hart Ziekenhuis (FV), Gouda, the Netherlands; MS Center, Department of Neuroscience, Imaging and Clinical Sciences (AL), University "G. d'Annunzio," Chieti, Italy; MS Center, Department of Neurology, First Medical Faculty (EH, DH), Charles University, Prague, Czech Republic; Center de Réadaptation Déficience Physique Chaudière-Appalache (PG), Levis; Hôpital Notre Dame (PD, AP), Montreal, Canada; Ospedali Riuniti di Salerno (G. Iuliano), Salerno, Italy; 19 Mayis University (M. Terzi), Medical Faculty, Turkey; Hospital Universitario Virgen Macarena (G. Izquierdo), Sevilla, Spain; Orbis Medical Centre (RMMH), Sittard-Geleen, the Netherlands; KTU Medical Faculty Farabi Hospital (CB), Trabzon, Turkey; Neurology Unit (EP, GG), ASUR Marche-AV3, Macerata; Nuovo Ospedale Civile S. Agostino (PS), Modena; AORN San Giuseppe Moscati (DLAS), Avellino, Italy; John Hunter Hospital (JL-S), Newcastle, Australia; Neurological Institute IRCCS Mondino (RB), Pavia, Italy; Neuro Rive-Sud (F. Grand'Maison), Hôpital Charles LeMoyne, Quebec, Canada; University of Parma (F. Granella), Italy; Department of Neurology (LK), University Hospital Basel, Switzerland; Department of Basic Medical Sciences, Neuroscience and Sense Organs (M. Trojano), University of Bari, Italy; and Department of Neurology (HB), Eastern Health, Monash University, Australia.

View Article and Find Full Text PDF
April 2016

How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis.

Expert Opin Drug Deliv 2015 15;12(12):1829-35. Epub 2015 Sep 15.

a 1 "Federico II" University, Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Science and Odontostomatology , Naples, Italy +39 08 17 46 37 64 ; +39 08 15 46 36 63 ;

View Article and Find Full Text PDF
May 2016

Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.

J Neuroinflammation 2015 Aug 12;12:146. Epub 2015 Aug 12.

Clinical Neurobiology Unit Neuroscience Institute Cavalieri Ottolenghi (NICO), Regione Gonzole 10, 10043, Orbassano, Turin, Italy.

View Article and Find Full Text PDF
August 2015

Comparative efficacy of switching to natalizumab in active multiple sclerosis.

Ann Clin Transl Neurol 2015 Apr 27;2(4):373-87. Epub 2015 Feb 27.

Department of Medicine and Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne Melbourne, Australia ; Department of Neurology, Eastern Health, Monash University Box Hill, Australia.

View Article and Find Full Text PDF
April 2015

Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial.

Neurology 2015 Mar 11;84(10):981-8. Epub 2015 Feb 11.

From the MRI Center for Neurological Diseases (L.R.), Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health (G.L.M., D.C.), and the Biostatistic Unit, Department of Health Sciences (M.P.S., L.R.), University of Genova; the Bone Marrow Transplantation Unit (F.G.), S. Martino Hospital, Genova, Italy; the Service of Neurology (A.S.) and the Hematology Department (E.C.), Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer, Hospital Clínic, University of Barcelona, Spain; the Department of Neurosciences (E.M.) and the Bone Marrow Transplantation Unit, Department of Hematology and Oncology (A.D.), University of Modena and Reggio Emilia; the MS Center, Department of Neuroscience, Imaging and Clinical Sciences (A.L.), University Gabriele D'Annunzio, Chieti-Pescara; the Bone Marrow Transplant Center, Department of Hematology (P.D.B.), Spirito Santo Hospital, Pescara; the Multiple Sclerosis Unit Ospedale Papa Giovanni XXIII (M.R.R.), Bergamo; the Hematology and Bone Marrow Transplant Unit Azienda Ospedaliera Papa Giovanni XXIII (A.R.), Bergamo; Division Neurology 1 (M.P.A.) and Division Neurology 2, Drug and Child Health (L.M., L.V.), Department of Neurosciences, and Bone Marrow Transplantation Unit (M.D.G., R.S.), Careggi University Hospital, University of Firenze; the Neuroimaging Research Unit (M.F.), Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan; the Department of Medical and Surgical Sciences (U.A.), Magna Graecia University of Catanzaro; the Advanced Cellular Therapy Center IRCCS "Istituto Tumori Giovanni Paolo II" Bari (P.I.), Italy; and the Internal Medicine and Vascular Disease Unit (D.F.), Assistance Publique Hospitaux de Paris (AP-HP) INSERM U 796, Paris 7 University, Saint-Louis Hospital, Paris, France.

View Article and Find Full Text PDF
March 2015

Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.

Expert Opin Drug Metab Toxicol 2015 Feb 16;11(2):295-306. Epub 2014 Dec 16.

University "G. d'Annunzio" of Chieti-Pescara, Department of Neuroscience, Imaging and Clinical Sciences , Via dei Vestini 31, Chieti, 66100 , Italy

View Article and Find Full Text PDF
February 2015

Fostering adherence to injectable disease-modifying therapies in multiple sclerosis.

Expert Rev Neurother 2014 Sep 11;14(9):1029-42. Epub 2014 Aug 11.

Department of Neuroscience, Imaging and Clinical Sciences, Multiple Sclerosis Center, University "G. d'Annunzio", Ospedale Clinicizzato "SS Annunziata", VII livello, Corpo A, Via dei Vestini snc, 66100 Chieti, Italy.

View Article and Find Full Text PDF
September 2014

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.

BMC Neurol 2014 Apr 1;14:65. Epub 2014 Apr 1.

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Largo Daneo 3, 16132 Genoa, Italy.

View Article and Find Full Text PDF
April 2014

Fingolimod after natalizumab and the risk of short-term relapse.

Neurology 2014 Apr 7;82(14):1204-11. Epub 2014 Mar 7.

From the Department of Medicine (V.G.J., T.K., H.B.), Melbourne Brain Centre (RMH), The University of Melbourne; Department of Neurology (V.G.J., V.L., T.K., H.B.), Royal Melbourne Hospital, Australia; Hospital Universitario Virgen Macarena (G.I.), Seville, Spain; Liverpool Hospital (S.H.), New South Wales, Australia; Amiri Hospital (R.A.), Kuwait City, Kuwait; John Hunter Hospital (J.L.-S.), Newcastle, Australia; MS Center (A.L.), Department of Neuroscience and Imaging, University "G. d'Annunzio," Chieti, Italy; Hôpital Notre Dame (P.D., M.G.), Montreal, Canada; Brain and Mind Research Institute (M.B.), Sydney, Australia; Neuro Rive-Sud (F.G.), Hôpital Charles LeMoyne, Quebec, Canada; Department of Basic Medical Sciences (M.T.), Neuroscience and Sense Organs, University of Bari, Italy; Flinders University and Medical Centre (M.S.), Adelaide, Australia; Ospedale di Macerata (G.G.), Italy; Geelong Hospital (C.S.), Australia; Karadeniz Technical University (C.B.), Trabzon, Turkey; AORN San Giuseppe Moscati (D.L.A.S.), Avellino, Italy; Groene Hart Ziekenhuis (F.V.), Gouda, the Netherlands; Department of Neurology (J.H., H.B.), Eastern Health Victoria; Monash University (J.H., H.B.), Melbourne; and Melbourne EpiCentre (D.L.), The University of Melbourne and Melbourne Health, Australia.

View Article and Find Full Text PDF
April 2014

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.

Neuropsychiatr Dis Treat 2013 24;9:893-914. Epub 2013 Jun 24.

Department of Neuroscience and Imaging, University "G d'Annunzio", Chieti, Italy.

View Article and Find Full Text PDF
July 2013

Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter study.

J Neurol 2013 May 21;260(5):1258-62. Epub 2012 Dec 21.

Department of Neurosciences, U.O.S.D. Malattie Demielinizzanti, A.O.U. Ospedali Riuniti di Salerno, piazza P.Paoli no 6, 84123 Salerno, Italy.

View Article and Find Full Text PDF
May 2013

RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence.

Expert Opin Drug Deliv 2013 Feb 20;10(2):273-83. Epub 2012 Dec 20.

Department of Neuroscience and Imaging, University G. d'Annunzio, c/o Centro Sclerosi Multipla, Ospedale Clinicizzato SS Annunziata, Via dei Vestini 31, 66100 Chieti, Italy.

View Article and Find Full Text PDF
February 2013

Relation between pro-inflammatory cytokines and acetylcholine levels in relapsing-remitting multiple sclerosis patients.

Int J Mol Sci 2012 Oct 3;13(10):12656-64. Epub 2012 Oct 3.

Department of Experimental and Clinical Sciences, University "G. d'Annunzio" Chieti-Pescara, Via Dei Vestini, 31 66100 Chieti, Italy.

View Article and Find Full Text PDF
October 2012